^
Association details:
| Biomarker: | STK11 mutation + KEAP1 mutation + KRAS G12C |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung Cancer
Published date:
08/17/2023
Excerpt:
CONTRADICTING EVIDENCE: The primary objective was to determine outcomes and determinants of response to first-line chemo-immunotherapy among patients with KRASG12C by evaluating objective response rate (ORR), progression-free survival (PFS), and overall survival (OS)....In a multivariable model for PFS, older age (P = .042), squamous cell histology (P = .008), poor ECOG performance status (PS) (P < .001), and comutations in KEAP1 and STK11 (KEAP1MUT/STK11MUT) (P = .015) were associated with worse PFS. In a multivariable model for OS, poor ECOG PS (P = .004) and KEAP1MUT/STK11MUT (P = .009) were associated with worse OS.
Secondary therapy:
Chemotherapy
DOI:
https://doi.org/10.1093/oncolo/oyad197
Source:
Title:
STK11 and KEAP1 mutations in non-small cell lung cancer patients: descriptive analysis and prognostic value among Hispanics (STRIKE registry-CLICaP)
Published date:
06/20/2022
Excerpt:
This retrospective study analyzed a cohort of Hispanic patients (N=103) diagnosed with mNSCLC from the US and seven Latin American countries (LATAM) treated with immune checkpoint inhibitors (ICI) alone or in combination...Among subgroups of co-mutations, PFS was significantly higher for patients whose tumors were STK11Mut+KEAP1Mut (especially when the KRASG12C mutation was found) [8.6 months (95%CI 6.8-11.5); p=0.005).
DOI:
https://doi.org/10.1016/j.lungcan.2022.06.010
